has a heart and soul

INTEGRATED AND PERSONALISED APPROACH IS THE PRIORITY ROAD TO MULTI-ORGAN FAILURE IN GENERAL, AND ALL DISEASES WITH MORTALITY
CRITICAL CARE. INTEGRATION OF MULTIPLE EXTRACORPOREAL CLEARANCE - WIDENS THE THERAPEUTIC OPPORTUNITIES IN CASE OF ORGAN FAILURE.

The soul of Amplya™: selective clearance

The blood is the part of the body that connects the organs. It enables survival and provides for cell growth and regulation thereby regulating the functionality of each organ. It transports nutrients and allows removing the waste products of cellular metabolism.

Complementary use of filtration and adsorption allows removing from the blood the molecules involved in organ damage without losing noble substances, such as albumin, and can encourage functional recovery of the organ.

AMPLEYA™ intervenes in this process by associating the specific treatment with the individual disease.

The soul of AMPLYA™ is an innovative concept born of the Collaborative Research between universities, clinics and the industry.

EFFICACY AND EFFICIENCY

OPTIMAL CONTAINMENT OF THE PREPARATION SINGLE MACHINE FOR THE WIDEST CHOICE OF ALSO IN MANAGEMENT EFFICACY AND EFFICIENCY.
Bibliography

1) Berlot G, et al.  
Coupled Plasma Filtration-Adsorption.  

2) Berlot G, et al.  
Changes in microvascular blood flow during coupled plasma filtration and adsorption.  
Anaesth Intensive Care 2011; 39: 687-9

NDT Plus (2011) 4: 285-8

4) Moretti R, et al.  
Minerva Anestesiol 2011 August; 77(8): 846-9

5) Caroleo S, et al.  
Coupled plasma filtration adsorption reduces serum bilirubin in a case of acute hypoxic hepatitis secondary to cardiogenic shock.  
Int J Artif Organs 2010; 33 (10): 749-52

6) Watten ML.  
Therapeutic approaches to reduce systemic inflammation in sepsis-associated neurologic complications.  

7) Formica M, et al.  
Coupled plasma filtration adsorption.  
Contrib Nephrol. 2007; 156:405-10

8) Mariano F, et al.  
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption.  

9) Ronco C, et al.  
Coupled plasma filtration adsorption: rationale, technical development and early clinical experience.  
Blood Purif 2003; 21:409-16

Hemodynamic response to coupled plasmaffiltration-adsorption in human septic shock.  
Intensive Care Med 2003; 29:703-8

Treatment of septic shock with the use of CPFA (coupled plasma filtration adsorption): impact on hemodynamic monitored with PICCO.  
G Ital Nefrol 2003; 20(3): 258-63

12) Ronco C, et al.  
A pilot study of coupled plasma filtration with adsorption in septic shock.  
Crit Care Med 2002; 30: 1260/5

Bellco S.r.l.  
Via Camurana, 1  
41037 Mirandola (MO) Italy  
Tel: +39 0535 29111  
Fax: +39 0535 25501  
bellco@bellco.net  
www.bellco.net
simply
“beyond”
“beyond”
Amplya™ for critical care operators

AMPLYA™ responds to the needs expressed by nursing and critical care staff offering:

- The simplicity of using one single system for the most varied treatments
- The tranquillity of automated and simple management of complex treatments 24 hours out of 24
- The reduction and optimisation of the number and time of the operations

Amplya™ for clinicians

AMPLYA™ responds to the needs expressed by clinicians offering:

- An unprecedented therapeutic choice
- An advanced and targeted personalisation capability
- Complete control of the therapeutic process

Therapeutic development

IN CRITICAL CARE, TACKLING ORGAN FAILURES IN REAL-TIME WITH AN EFFECTIVELY FACE DISEASES SUCH AS: SEPSIS, RENAL, RESPIRATORY AND RATES STILL ABOVE 50%. AMPLYA™ IS A MULTITHERAPEUTIC SYSTEM FOR TREATMENTS - FROM THE MORE CONVENTIONAL TO ADSORPTION TREATMENTS

Ampleya™ for patients

An acute patient in critical care may suffer from often lethal or crippling organ failure or ‘multi-organ failure’.

AMPLYA™ offers acute patients:

- The possibility of receiving the most suitable treatment
- An advanced capability of treatment personalisation and fast intervention
- An advanced support in case of organ failure

B E Y O N D  M A N A G E M E N T

WITH AMPLYA™, ADVANCED AUTOMATION, AND MANAGEMENT TIMES, AVAILABILITY OF A TREATMENTS MAKE IT POSSIBLE TO “GO BEYOND”
AMPLYA™ is capable of performing a vast number of extracorporeal blood clearance treatments with one single circuit.

For each specific disease, an unprecedented integrated therapeutic approach that can aid patient survival and improve the quality of life.

AMPLYA™: A LIFE-SAVING SYSTEM

AMPLYA™ is capable of performing a vast number of extracorporeal blood clearance treatments with one single circuit.

For each specific disease, an unprecedented integrated therapeutic approach that can aid patient survival and improve the quality of life.

AMPLYA™: A wide therapeutic choice
THE HISTORY OF BELLCO IN MANY WAYS IDENTIFIES WITH THE HISTORY OF EXTRACORPOREAL BLOOD CLEARANCE: CONSTANT COMMITMENT AND PASSION AT THE SERVICE OF COLLABORATIVE RESEARCH.

PAYING ATTENTION AND LISTENING TO THE NEEDS OF THE MEDICAL-SCIENTIFIC COMMUNITY TOGETHER WITH KNOW-HOW AND INNOVATIVE CAPABILITY TODAY MAKE IT POSSIBLE TO TAKE ANOTHER STEP FORWARD ON THE ROAD TO EXCELLENCE.

THE CURRENT AND FUTURE CHALLENGES IN CRITICAL CARE REQUIRE INTUITIVE, VERSATILE SYSTEMS ABLE TO RESPOND TO THE CLINICAL NEEDS IN REAL-TIME.

AMPLYA™: A real and complete multitherapeutic system.
A single platform for multiple options.

- CRRT (SCUF, CVVH, CVVHD, CVVHDF)
- IRRT (IHF-HVHF, IHD SLED, IHDF)
- PEX
- CPFA®
- CASCADE FILTRATION
- CO₂ REMOVAL (ABYLCAP & ABYLCAP HD)
Innovative treatments open to new horizons
All kidney replacement treatments
Innovative and specific sorbents
Systemic or locoregional anticoagulation systems
One single set of lines couplable to six blood filters
Low- and high-flux treatments
Direct and continuous hematocrit and oxygen saturation reading
High treatment autonomy thanks to 3 high-capacity scales

THE RIGHT THERAPY WAY

THE RIGHT T

AMPLYA™

ACUTE MULTITHERAPEUTIC SYSTEM

HOW

The added value Amplya™

COMPLETENESS
- Innovative treatments open to new horizons
- All kidney replacement treatments
- Innovative and specific sorbents
- Systemic or locoregional anticoagulation systems
- One single set of lines couplable to six blood filters
- Low- and high-flux treatments
- Direct and continuous hematocrit and oxygen saturation reading
- High treatment autonomy thanks to 3 high-capacity scales

AUTOMATION
- Double cassette plug & play system
- Fast and safe disposable installation
- Fully automated preparation and treatment
- Personalised CPFA® management with controlled servo-assisted flows
- Automatic level control
- Optical self-recognition of the disposable kit
- Over 300 hours of stored data consultable on PC

INTUITIVENESS
- Touch screen
- Immediate operator interface
- Flexibility in the operating sequence
- One cassette system for all treatments

For patients that may be victims of diseases such as:
ALI (ACUTE LUNG INJURY); RHEUMATOID ARTHRITIS;
ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME); COBP
(CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY);
CRUSH SYNDROME; HYPERCHOLESTEROLEMIA; ARF
(ACUTE RENAL FAILURE); MYASTHENIA GRAVIS; MYELOMA;
MOF: MULTI-ORGAN DYSFUNCTION (RENAL, HEPATIC,
CARDIAC, PULMONARY AND CEREBRAL); IMMUNE
COMPLEX DISEASES; SEVERE SEPSIS; SEPTIC SHOCK.
Selective Clearance: beyond the known patterns

Just as the organism in physiological conditions retains noble substances and eliminates waste products, so selective clearance in pathological conditions can be truly effective if it retains noble substances and eliminates toxic ones.

Develop new clearance technologies, increasingly effective in providing therapeutic support for complex diseases.

This is the commitment of the Collaborative Research of universities, clinics and the industry, also testified by the F.A.R.E. Project: Filtration and Adsorption Regione Emilia-Romagna.